<DOC>
	<DOCNO>NCT00580840</DOCNO>
	<brief_summary>During run-in period , CZP administer 400 mg ( 2 injection ) Wks 0 , 2 , 4 200 mg placebo ( 1 injection placebo , 1 injection CZP ) Wks 6 , 8 , 10 , 12 , 14 16 . At Wk 18 patient group responder non-responders base result ACR20 Week 16 .</brief_summary>
	<brief_title>Dosing Flexibility Study Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Subjects stable methotrexate ( MTX ) dose enter run-in period certolizumab pegol ( CZP ) administer dose 400 mg ( 2 injection ) Weeks 0 , 2 , 4 dose 200 mg placebo ( 1 injection placebo , 1 injection CZP ) Weeks 6 , 8 , 10 , 12 , 14 16 . The dose MTX stable least 2 month prior Baseline visit remain stable throughout trial , unless need reduce dose reason toxicity . At Week 18 visit , subject ACR20 ( American College Rheumatology 20 % Improvement ) responders Week 16 randomize double-blinded way receive either 400 mg CZP give every 4 week placebo give every 4 week give two injection ( alternate CZP placebo every two week ) plus MTX , 200 mg CZP placebo administer every 2 week ( one injection ) plus MTX , Placebo administer two injection every 2 week plus MTX . Non-responders withdrawn study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Patients establish adult rheumatoid arthritis currently Methotrexate least 3 month All concomitant disease pathological condition could interfere impact assessment study treatment Previous clinical trial participation previous biological therapy could interfere result present clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Joint Disease</keyword>
	<keyword>Arthritis</keyword>
	<keyword>Certolizumab pegol</keyword>
	<keyword>Cimzia</keyword>
</DOC>